Getagraph.com logo
S&P 500
(0.91%) 5 064.20 points
Dow Jones
(0.85%) 38 226 points
Nasdaq
(1.51%) 15 841 points
Oil
(0.30%) $79.19
Gas
(0.15%) $2.04
Gold
(0.13%) $2 312.70
Silver
(0.25%) $26.90
Platinum
(0.05%) $963.10
USD/EUR
(-0.04%) $0.932
USD/NOK
(-0.06%) $10.98
USD/GBP
(-0.07%) $0.797
USD/RUB
(-0.01%) $91.11

Realaus laiko atnaujinimai Sosei Group Corporation [4565.T]

Birža: JPX Sektorius: Healthcare Pramonė: Biotechnology
Atnaujinta2 geg. 2024 @ 09:15
25% discount on Stockinvest.us - Use code: Podcast

1.67% ¥ 1 519.00

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 09:15):

Sosei Group Corporation develops biopharmaceutical products worldwide. Its marketed products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair to treat asthma; and ORAVI, an oropharyngeal candidiasis...

Stats
Šios dienos apimtis 644 100
Vidutinė apimtis 1.35M
Rinkos kapitalizacija 135.87B
EPS ¥-2.13 ( 2024-02-13 )
Kita pelno data ( ¥35.75 ) 2024-05-08
Last Dividend ¥2.50 ( 2015-03-27 )
Next Dividend ¥0 ( N/A )
P/E -17.41
ATR14 ¥1.040 (0.07%)

Tūris Koreliacija

Ilgas: -0.14 (neutral)
Trumpas: -0.10 (neutral)
Signal:(53.491) Neutral

Sosei Group Corporation Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Sosei Group Corporation Koreliacija - Valiuta/Žaliavos

The country flag -0.73
( moderate negative )
The country flag -0.73
( moderate negative )
The country flag 0.58
( weak )
The country flag -0.53
( weak negative )
The country flag -0.68
( moderate negative )
The country flag 0.68
( moderate )

Sosei Group Corporation Finansinės ataskaitos

Annual 2023
Pajamos: ¥12.77B
Bruto pelnas: ¥7.87B (61.62 %)
EPS: ¥-87.17
FY 2023
Pajamos: ¥12.77B
Bruto pelnas: ¥7.87B (61.62 %)
EPS: ¥-87.17
FY 2022
Pajamos: ¥15.57B
Bruto pelnas: ¥14.64B (94.05 %)
EPS: ¥4.67
FY 2021
Pajamos: ¥17.71B
Bruto pelnas: ¥16.78B (94.73 %)
EPS: ¥12.53

Financial Reports:

No articles found.

Sosei Group Corporation Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
¥0
(N/A) 		¥0
(N/A) 		¥0
(N/A) 		¥0
(N/A) 		¥0
(N/A) 		¥0
(N/A) 		¥0
(N/A) 		¥0
(N/A) 		¥0
(N/A) 		¥0
(N/A)

Sosei Group Corporation Dividend Information - No Dividend Player

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future
Information
First Dividend ¥2.50 2015-03-27
Last Dividend ¥2.50 2015-03-27
Next Dividend ¥0 N/A
Payout Date 0000-00-00
Next Payout Date N/A
# dividends 1 --
Total Paid Out ¥2.50 --
Avg. Dividend % Per Year 0.00% --
Score 0.01 --
Div. Sustainability Score 0
Div.Growth Potential Score 0
Div. Directional Score 0 --
Next Divdend (Est)
 (2024-05-02)
¥0 Estimate 0.00 %
Dividend Stability
0.01 Very Bad
Dividend Score
0.01
Pay Frequency
Insufficient data to determine frequency
Yearly Payout
Year Amount Yield

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Top 10 dividend Companies for JPX

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
9078.T Ex Dividend Knight 2023-09-28 Semi-Annually 0 0.00%
7971.T Ex Dividend Junior 2023-09-28 Annually 0 0.00%
7199.T Ex Dividend Junior 2023-09-28 Semi-Annually 0 0.00%
6455.T Ex Dividend Knight 2023-09-28 Semi-Annually 0 0.00%
5451.T Ex Dividend Knight 2023-09-28 Semi-Annually 0 0.00%
4442.T Ex Dividend Junior 2024-03-28 Insufficient data to determine frequency 0 0.00%
3636.T Ex Dividend Knight 2023-09-28 Semi-Annually 0 0.00%
2882.T Ex Dividend Junior 2024-02-28 Semi-Annually 0 0.00%
1663.T Ex Dividend Knight 2023-12-28 Semi-Annually 0 0.00%
9757.T Ex Dividend Knight 2023-12-28 Semi-Annually 0 0.00%

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM-0.5631.500-10.00-10.00[0 - 0.5]
returnOnAssetsTTM-0.04581.200-1.525-1.830[0 - 0.3]
returnOnEquityTTM-0.1171.500-2.41-3.62[0.1 - 1]
payoutRatioTTM0-1.00000[0 - 1]
currentRatioTTM3.790.80010.008.00[1 - 3]
quickRatioTTM3.570.80010.008.00[0.8 - 2.5]
cashRatioTTM2.861.50010.0010.00[0.2 - 2]
debtRatioTTM0.445-1.5002.58-3.87[0 - 0.6]
interestCoverageTTM-3.341.000-2.35-2.35[3 - 30]
operatingCashFlowPerShareTTM-58.952.00-10.00-10.00[0 - 30]
freeCashFlowPerShareTTM-68.472.00-10.00-10.00[0 - 20]
debtEquityRatioTTM1.048-1.5005.81-8.71[0 - 2.5]
grossProfitMarginTTM0.6971.0001.7231.723[0.2 - 0.8]
operatingProfitMarginTTM-0.6921.000-10.00-10.00[0.1 - 0.6]
cashFlowToDebtRatioTTM-0.07531.000-1.530-1.530[0.2 - 2]
assetTurnoverTTM0.08120.800-2.79-2.23[0.5 - 2]
Total Score-1.525

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM-18.961.000-2.020[1 - 100]
returnOnEquityTTM-0.1172.50-1.551-3.62[0.1 - 1.5]
freeCashFlowPerShareTTM-68.472.00-10.00-10.00[0 - 30]
dividendYielPercentageTTM01.50000[0 - 0.4]
operatingCashFlowPerShareTTM-58.952.00-10.00-10.00[0 - 30]
payoutRatioTTM01.50000[0 - 1]
pegRatioTTM0.3021.500-1.3180[0.5 - 2]
operatingCashFlowSalesRatioTTM-0.4131.000-10.000[0.1 - 0.5]
Total Score-3.79

Sosei Group Corporation

Sosei Group Corporation develops biopharmaceutical products worldwide. Its marketed products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair to treat asthma; and ORAVI, an oropharyngeal candidiasis. The company's product pipeline consists of HTL0022562, a calcitonin gene related peptide antagonist, which is in Phase I clinical study; HTL0016878 for neurological diseases; PF-07081532 for Type 2 diabetes mellitus and obesity; PF-07054894 for inflammatory bowel disease; PF-07258669 for anorexia; and TMP301 and BHV3100 for neurological disorders, which is in clinical trials. Sosei Group Corporation has a strategic collaboration with AbbVie, Biohaven, Genentech, GSK, Takeda, Pfizer, AstraZeneca, and Takeda. The company was incorporated in 1990 and is headquartered in Tokyo, Japan.

Apie Signalai gyvai

Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.

Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.